Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
Tag Archive for: clinical trials
Introduction to Ra Pharma & the Potential of Zilucoplan for the Treatment of IMNM Webinar
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Ben Matys, Sr. Clinical Trial Manager, and Ramin Farzaneh-Far, Chief Medical Officer of Ra Pharma, joined MSU) on November...
A Phase 2 Study of Zilucoplan in Patients with Immune-Mediated Necrotizing Myopathy
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
We are excited to announce our partnership with Ra Pharma for RA101495-02.202: A Phase 2 Study of Zilucoplan in...
Second Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Watch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...
Learn about how clinical trials work in this educational and interactive video session led by Lindsey Wahlstrom-Edwards, Head of...
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
Corbus launches DETERMINE, a Phase 3 trial of lenabasum for the treatment of dermatomyositis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
New locations announced July 9, 2019. DETERMINE is a double-blind, placebo-controlled 1-year study designed to test the efficacy and...
MSU and Orphazyme: Working together for a treatment for inclusion body myositis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Updated April 23, 2019 - Study is fully enrolled. One of our goals is to provide inclusion body...
Lenabasum for dermatomyositis receives orphan designation in the European Union
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Today, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
New Study for Patients with Inclusion Body Myositis (IBM) at Yale
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
We would like to let you know about a clinical research study that is available for patients diagnosed with...
Corbus Pharmaceuticals announced today that they will proceed with a Phase 3 clinical trial to evaluate the efficacy and...
Corbus Pharmaceuticals will host Jerry Williams, the Founder and President of MSU, Heather Spadaccini, Jerry’s friend and part-time caregiver,...
MSU, a patient-centered 501(c)(3) nonprofit organization, is proud to announce a partnership with Antidote Technologies, a digital health company...
Orphazyme formally assumes the sponsorship of Phase II/III arimoclomol trial for sIBM
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme formally assumes the...
FDA grants Orphazyme drug arimoclomol orphan drug designation in the U.S.
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Orphazyme A/S, a Danish biotech company with a late-stage orphan drug pipeline, today announced that the U.S. Food and...
Investigators are seeking people with dermatomyositis to participate in a phase 2 clinical trial of the experimental drug IMO-8400....
Clinical trials for Myositis and other rare diseases is an essential step to finding safe and effective treatments. There...